MOESM4 of Enrichment of superoxide dismutase 2 in glioblastoma confers to acquisition of temozolomide resistance that is associated with tumor-initiating cell subsets

  • Chia Hung Chien (Contributor)
  • Jian-Ying Chuang (Contributor)
  • Shung-Tai Yang (Contributor)
  • Wen-Bin Yang (Contributor)
  • Pin Yuan Chen (Contributor)
  • Tsung-I Hsu (Contributor)
  • Chih Yuan Huang (Contributor)
  • Wei-Lun Lo (Contributor)
  • Ka-Yen Yang (Contributor)
  • Ming Sheng Liu (Contributor)
  • Jui Mei Chu (Contributor)
  • Pei Hsuan Chung (Contributor)
  • Jr Jiun Liu (Contributor)
  • Shao Wen Chou (Contributor)
  • Shang Hung Chen (Contributor)
  • Kwang Yu Chang (Contributor)

Dataset

Description

Additional file 4: Figure S4. The resistant primary cells (GBM#1) were pretreated with siRNA for SOD2 knockdown. The cells were then incubated in low serum (2%) cultures medium with or without TMZ. The western blotting result of cleaved caspase 3 after TMZ treatment was shown. (n = 3 for each group, Data are presented as mean ± standard error, *P
Date made availableOct 19 2019
PublisherUnknown Publisher

Cite this